Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two awards have been announced for scientists in the WIMM.

 

oni_chowdhury

Oni Chowdhury has been awarded an NIHR clinical lectureship. This will enable Oni to incorporate the remainder of her specialist clinical training with research. She will be working on the therapeutic targeting of malignant stem cells with the Stem Cell Group in the WIMM.

648A3130

Chris Babbs has been awarded a 3 year project grant, funded by Action Medical Research for Children, to identify new alleles and genes underlying Congenital Dyserythropoietic Anaemia type I, a variable anaemia that manifests in childhood. Coding mutations in the genes previously shown to underlie this disease explain only ~60% of cases, strongly suggesting the presence of occult pathogenic alleles or the involvement of a further locus. Identification of further genetic lesions will improve molecular diagnosis and is likely to shed light on the pathogenic mechanism underlying this disorder. The defining cellular characteristic of this anaemia is abnormal chromatin formation in erythroblast nuclei, suggesting that all causative mutations affect a pathway critical for chromatin assembly or compaction in maturing erythroblasts. By introducing specific mutations into induced pluripotent stem cells we hope to shed light on the pathogenic mechanism and establish a high throughput screening system to test small molecules as potential therapy for this disorder.

Congratulations to both of them.

Similar stories

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.